The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...

The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...